RSK3/RPS6KA2 & RSK2/RPS6KA3 Drug Discovery Landscape & Assay Solutions
- By admin
- 03 Oct 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Rare Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RSK3 and RSK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RSK3/RPS6KA2 Active Kinase Domain / RSK2/RPS6KA3 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RSK3 Products |
| Gene Delivery | RSK2/RSK3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling assays. |
View RSK2 Products |
| Benchmark Ab | Anti-RSK2 / Anti-RSK3 Reference Antibody Recombinant positive control for Western Blot, ELISA, and Flow Cytometry. |
View RSK2 Products |
| Validator | RSK2 / RSK3 siRNA Set For target knockdown verification and pathway specificity confirmation. |
View RSK3 Products |
| Related Target A | RSK1 (RPS6KA1) Homologue selectivity screening to avoid off-target toxicity. |
View RSK1 Products |
| Related Target B | ERK2 (MAPK1) Upstream activating kinase crucial for RSK phosphorylation cascade. |
View ERK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Domain Homology Selectivity | Human RSK1, RSK2, RSK3, and RSK4 recombinant proteins strictly verified by Mass Spectrometry for isoform-specific screening. |
| ATP-Competitive vs. Allosteric Profiling | Truncated N-terminal (NTKD) and C-terminal (CTKD) active kinase domain constructs available. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RSK3 & RSK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RSK (Ribosomal S6 Kinase) family therapeutics is intensifying, with major players shifting focus from pan-RSK inhibition to isoform-selective small molecules. RSK2 (RPS6KA3) and RSK3 (RPS6KA2) represent critical downstream effectors of the MAPK/ERK pathway. While RSK2 is highly implicated in breast cancer, prostate cancer, and Coffin-Lowry syndrome, RSK3 has emerged as a key driver of resistance to PI3K/mTOR inhibitors in hormone receptor-positive breast cancers. As first-generation pan-RSK inhibitors face toxicity limitations, the next wave of R&D is targeting highly selective allosteric binders and PROTAC degraders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Kinase Inhibitor) | PMD Therapeutics, Boehringer Ingelheim | Triple-Negative Breast Cancer (TNBC), Ovarian Cancer | Selectivity Assay (Need WT vs Mutant/Subfamily Proteins) |
| PROTAC (Degrader) | Academic / Biotech Spinoffs | Prostate Cancer, Refractory Solid Tumors | Target Engagement Verification (Need High-Purity RSK2/3 Proteins) |
| Gene Therapy | Rare Disease Consortia | Coffin-Lowry Syndrome (RSK2 deficiency) | Overexpression Validation (Need Lentivirus for Stable Cell Lines) |